Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Ixabepilone|DRUG: Ixabepilone
Sponsor: R-Pharm
Collaborators: US Oncology Research